



Apex Medical Corp.

2020 The Second Investor Conference

Nov. 18th , 2020



2020Q3 YTD Consolidated Income Statement

Unit: NTDK

	2020Q3 YTD Review	2019Q3 YTD Review	'20/'19 Var.(\$)	'20/'19 Var.(%)
Net Sales	1,450,232	1,519,848	(69,616)	-5%
Gross Profit	629,838	638,485	(8,647)	-
Gross Margin(%)	43%	42%	-	-
Operating Expenses	531,514	543,698	(12,184)	-2%
Income before Tax	115,110	97,799	17,311	18%
Net Income attributed to owner of the parent company	90,655	68,608	22,047	32%
Basic EPS(NT\$)	0.90	0.68	-	-



2020/09/30 Consolidated Balance Sheet(1)

Unit: NTDK

	2020/09/30 Review	2019/09/30 Review	Variance	
	Amount	Amount	Amount	%
Cash and cash equivalent	657,974	357,358	300,616	84%
Current financial assets at fair value through profit or loss	95,219	128,499	(33,280)	-26%
Amortized cost financial assets	70,883	391,592	(320,709)	-82%
Accounts receivable	251,763	299,695	(47,932)	-16%
Inventories	437,661	428,178	9,483	2%
Total current assets	1,593,733	1,700,869	(107,136)	-6%
Investments accounted for using equity method	0	206,647	(206,647)	-100%
Property, plant and equipment	781,395	663,512	117,883	18%
Right-of-use asset	80,178	105,645	(25,467)	-24%
Intangible Assets	685,184	424,109	261,075	62%
Other non-current assets	769	52,079	(51,310)	-99%
Total non-current assets	1,619,343	1,511,656	107,687	7%
Total Assets	3,213,076	3,212,525	551	0%

Note: Only important accounts are listed in the table.



2020/09/30 Consolidated Balance Sheet(2)

Unit: NTDK


	2020/09/30 Audited	2019/09/30 Audited	Variance	
	Amount	Amount	Amount	%
Short-term debt	382,423	306,657	75,766	25%
Accounts payable and other payable*	353,295	307,484	45,811	15%
Other current liabilities*	106,932	65,368	41,564	64%
Bonds payable – current	0	299,722	(299,722)	-100%
Total current liabilities	921,096	1,022,224	(101,128)	-10%
Long-term debt	163,607	96,002	67,605	70%
Lease liabilities	56,361	77,348	(20,987)	-27%
Total long-term liabilities	229,117	183,188	45,929	25%
Total liabilities	1,150,213	1,205,412	(55,199)	-5%
Total share capital	1,009,116	1,009,116	0	0%
Additional paid-in capital	345,635	345,635	0	0%
Total retained earnings	895,050	831,102	63,948	8%
Other equity	(190,776)	(182,645)	(8,131)	4%
Owners' equity attributed to the parent company	2,059,025	2,003,208	55,817	3%
Total owners' equity	2,062,863	2,007,113	55,750	3%
Total liabilities and owners' equity	3,213,076	3,212,525	551	0%

Note: Only important accounts are listed in the table ; *the accounts payable and other payable including the amount belong to the related parties.




2020Q3YTD Sales by Department

2020/09 YTD Act.




2019/09 YTD Act.






2020Q3YTD Sales by Product

2020/09 YTD Act.



2019/09 YTD Act.





Operating Status or Events (1)

- ◆ Apex Medical fully acquires the shares of SLK Vertriebs GmbH and SLK Medical in Sep. 2020.

With this acquisition, Apex Medical reinforces its market position in delivering more comprehensive product portfolio and service in Germany and Europe. It is expected to have IPC and Hoist from SLK as the new supplement to Apex Medical's product line.



- ◆ SLK Vertriebs GmbH與SLK Medical GmbH
 - ① Operating Site: Waltrop, Germany
 - ② Founded : SLK-V: Year 1998, SLK-M: Year 2003
 - ③ Headcount : SLK-V: 79 、 SLK-M: 19 (2020/09, permanent staff)
 - ④ Sales Revenue : SLK-V 2020/09YTD euro 9.65 million
SLK-M 2020/09YTD euro 0.82 million
 - ⑤ Main Business :
SLK-V : Research, Manufacture, Sales, Repairs, Cleaning and Other Services; Focus on Home Care Channels
SLK-M : Sales and Rental Service for Hospital Channels
 - ⑦ Sales Region: Inside Germany

Major Products of SLK



ALTERNATING
PRESSURE SYSTEMS



FOAM PRODUCTS



PATIENT HOISTS



INTERMITTENT PNEUMATIC
COMPRESSION





Operating Status or Events (2)

- ◆ Medium-Term and Long-Term Development Strategy:
 1. Increase new customers and build global “Branding Agency Partners”
 2. Wound Management: Multi-channel engagement to increase market share
 3. Expansion of OBM in North America
 4. Respiratory Treatment: “Mask” Adventure
 5. Autoclave: business development in North America



<http://www.apexmedicalcorp.com>

IR@apexmedicalcorp.com